Data from an early-stage trial assessing an induction cycle consisting of Janssen Cilag's Dacogen, or decitabine, succeeded twice a week by Karyopharm Therapeutics' Xpovio, or selinexor, resulted in significant clinical activity in 25 poor-risk patients with relapsed or refractory acute myeloid leukemia, five of whom were older patients newly diagnosed with AML. Details of the trial were reported in online in the journal Leukemia & Lymphoma.
Poor-risk AML patients may benefit from novel induction cycle
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.